{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-001411","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.837218+00:00","generated_at":"2026-06-22T23:39:36.471703+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alnylam Q3 net product revenue $232M (+39% YoY); AMVUTTRA Q3 sales $25M; reiterates FY product revenue guide $870-930M","bullets":["Q3 2022 GAAP net loss $405.9M ($3.32/sh) vs $204.5M ($1.72/sh) YoY; non-GAAP net loss $193.4M ($1.58/sh) vs $189.8M ($1.59/sh).","Combined net product revenue $232M: TTR $170M (ONPATTRO $145M, AMVUTTRA $25M), GIVLAARI $46M, OXLUMO $16M.","Reiterated FY 2022 product revenue guidance $870-$930M; lowered collaboration/royalty guidance to $100-$150M from $175-$225M.","AMVUTTRA U.S. launch strong: $25M net rev in first full quarter, 475 Start Forms, 46% new patients, 54% switches from ONPATTRO.","Positive APOLLO-B Phase 3 results for patisiran in ATTR cardiomyopathy; sNDA submission on track for late 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-001411","json":"https://secwatch.observer/filing/0001157523-22-001411.json","markdown":"https://secwatch.observer/filing/0001157523-22-001411.md","text":"https://secwatch.observer/filing/0001157523-22-001411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000115752322001411/0001157523-22-001411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000115752322001411/a52953758.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:39:36.471703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}